Navigation Links
Hospira Names John B. Elliot Senior Vice President of Operations
Date:4/11/2012

LAKE FOREST, Ill., April 11, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that John B. Elliot has been named senior vice president, Operations, effective April 16. In this role, Mr. Elliot will have overall responsibility for Hospira's global operations organization and serve as a member of Hospira's senior leadership team. He will report directly to F. Michael Ball, chief executive officer.

"John is a seasoned global leader with more than 35 years of broad manufacturing experience across production, logistics and supply, and specific expertise in injectable pharmaceuticals," said Mr. Ball. "With his proven track record in driving improvements in quality, service and operational effectiveness, we're confident John will have an immediate, positive impact as we continue our efforts to deliver high-quality, cost-effective products to customers and ultimately establish our manufacturing operations as a strategic, competitive advantage."

Mr. Elliot, 60, has most recently advised some of the world's largest pharmaceutical companies in his role as an operations consultant. He previously served as president and chairman at Cherokee Pharmaceuticals, LLC (subsequently acquired by Merck & Co.), a U.S.-based active ingredients manufacturing company, where he led the organization from start-up to become a significant competitor in the contract manufacturing marketplace. Prior to Cherokee, Mr. Elliot spent 26 years with GlaxoSmithKline plc (formerly SmithKline Beecham), most recently serving as senior vice president. During his tenure, he held various roles of progressive responsibility in the operations organization and was credited for inculcating a high-performance culture across his plant network.

Under Mr. Elliot's leadership, Hospira will advance its plant remediation strategies and create additional manufacturing capacity, including the construction of a new 1.1 million square-foot, state-of-the-art facility in India. Mr. Elliot joins an operations leadership team that has recently been strengthened by the addition of top industry talent, including the appointment of Zena G. Kaufman as Hospira's new senior vice president of Quality in February.

Born and educated in Scotland, Mr. Elliot earned his bachelor's degree, with honors, in chemical engineering from Heriot-Watt University in Edinburgh.

About Hospira
Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 15,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Hospira Names Zena G. Kaufman Senior Vice President of Quality; Strengthens Quality and Compliance Capabilities With Addition of Top Industry Talent
2. Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement
3. Hospira Receives Favorable Court Decision on Eloxatin(R)
4. Hospira Announces Plans to Integrate Symbiq(R) and EndoTool(R) Technologies
5. Hospira Names Brian Meadows Supply Chain Chief
6. Hospira Supports Newly Introduced Biogenerics Legislation
7. Hospira Advances Patient Safety With New GemStar(R) SP Infusion System
8. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
9. Hospira Hosts Conference Call for Third-Quarter 2008 Earnings
10. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
11. Health Diagnostic Laboratory Names Scott Blackwell Vice President of Corporate Culture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):